The US Food and Drug Administration asked COVID-19 vaccine manufacturers to develop modified bivalent vaccines that add an Omicron BA.4/BA.5 spike component to the current vaccine composition for use as booster shots as early as fall 2022. The agency plans to stick with the prototype COVID vaccines as the primary series for now.
That move announced 30 June will likely force the FDA to accept much less rigorous data for the updated...







